106 related articles for article (PubMed ID: 2678584)
1. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock.
Pralong G; Calandra T; Glauser MP; Schellekens J; Verhoef J; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Jun; 61(3):459-62. PubMed ID: 2678584
[TBL] [Abstract][Full Text] [Related]
2. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Mesters RM; Flörke N; Ostermann H; Kienast J
Thromb Haemost; 1996 Jun; 75(6):902-7. PubMed ID: 8822584
[TBL] [Abstract][Full Text] [Related]
3. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
[TBL] [Abstract][Full Text] [Related]
4. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
5. TAFI and PAI-1 levels in human sepsis.
Zeerleder S; Schroeder V; Hack CE; Kohler HP; Wuillemin WA
Thromb Res; 2006; 118(2):205-12. PubMed ID: 16009400
[TBL] [Abstract][Full Text] [Related]
6. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
7. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
[TBL] [Abstract][Full Text] [Related]
8. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.
Kruithof EK; Gudinchet A; Bachmann F
Thromb Haemost; 1988 Feb; 59(1):7-12. PubMed ID: 3129809
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
12. Serum cardiac troponin-T as a prognostic marker in septic shock.
Choon-ngarm T; Partpisanu P
J Med Assoc Thai; 2008 Dec; 91(12):1818-21. PubMed ID: 19133515
[TBL] [Abstract][Full Text] [Related]
13. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
Miyamoto S; Kawano H; Takazoe K; Soejima H; Sakamoto T; Hokamaki J; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
Thromb Res; 2004; 113(6):345-51. PubMed ID: 15226088
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
19. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
20. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
